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Abstract
Regulated protein destruction by the proteasome is crucial for the maintenance of normal cellular
homeostasis. Much of our understanding of proteasome function stems from the use of drugs that
inhibit its activity. Curiously, despite the importance of proteasomal proteolysis, previous studies
have found that proliferation of the yeast Saccharomyces cerevisiae is relatively resistant to the
effects of proteasome inhibitors such as MG132, even in the presence of mutations that increase
inhibitor levels in cells. We reasoned that part of the resistance of S. cerevisiae to proteasome
inhibitors stems from the fact that most proteasome inhibitors preferentially target the
chymotryptic activity of the proteasome, and that the caspase-like and tryptic sites within the 20S
core could compensate for proteasome function under these conditions. To test this hypothesis, we
generated a strain of yeast in which the gene encoding the drug efflux pump Pdr5 is deleted, and
the tryptic and caspase-like proteasome activities are inactivated by mutation. We find that this
strain has dramatically increased sensitivity to the proteasome inhibitor MG132. Under these
conditions, treatment of yeast with MG132 blocks progression through the cell cycle, increases the
accumulation of polyubiquitylated proteins and decreases the ability to induce transcription of
certain genes. These results highlight the contribution of the caspase-like and tryptic activities of
the proteasome to its function, and provide a strategy to potently block proteasomal proteolysis in
yeast that has practical applications.
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In eukaryotes, the proteasome is a critical complex for the regulated destruction of proteins
that removes misfolded, damaged and short-lived proteins targeted by ubiquitylation
(Goldberg, 2003). The hydrolysis of peptides by the proteasome not only prevents the toxic
accumulation of abnormal proteins but also regulates processes such as cell cycle
progression (King et al., 1996; Zachariae and Nasmyth, 1999), DNA repair (Daulny and
Tansey, 2009; Krogan et al., 2004), transcription (Collins and Tansey, 2006), protein quality
control (Goldberg, 2003) and organelle distribution (Campbell et al., 1994). Consequently,
nearly all genes encoding proteasome subunits are necessary for the viability of the yeast
Saccharomyces cerevisiae (Giaever et al., 2002), and defects in the ubiquitin–proteasome
system underlie, at least in part, several human diseases (Schwartz and Ciechanover, 1999).
The 26S proteasome is separable into two distinct subcomplexes: the 19S regulatory particle
and the 20S core particle (Groll et al., 1997). Within the 20S core reside three distinct
proteolytic activities, chymotrptic-, tryptic- and caspase-like, each contained within a
separate β-subunit (Pre2, Pup1, and Pre3, respectively) (Arendt and Hochstrasser, 1997;
Heinemeyer et al., 1997). This collection of different substrate specificities presumably
endows the proteasome with the capacity to efficiently degrade a diverse set of substrates,
although it is generally accepted that the chymotryptic activity of the proteasome is most
important for its function. Indeed, mutations that inactivate the chymotryptic protease (Pre2)
significantly stabilize the degradation of reporter proteins such as α2 or Ub-β gal fusions,
whereas mutations that inactivate the trypsin- (Pup1) and caspase-like (Pre3) proteases result
in only modest effects on the turnover of these model proteasome substrates (Arendt and
Hochstrasser, 1997, 1999; Heinemeyer et al., 1997).
Given the predominant role of the chymotryptic site of the proteasome, much effort has been
placed on the development of small molecule inhibitors that block its function. A handful of
compounds have been developed (Groll et al., 2009) that typically block the chymotryptic
site by forming covalent or pseudocovalent adducts with the catalytic threonine within this
subunit. These inhibitors have been extremely valuable in elucidating the biological role of
the proteasome in metazoan settings (e.g. Rock et al., 1994) and in the identification of
proteasome substrates (Mayor et al., 2007). Consistent with the central importance of
proteasomal proteolysis in cellular homeostasis, treatment of mammalian cells with
proteasome inhibitors such as MG132 or bortezomib results in rapid cell cycle arrest and the
induction of apoptosis, and indeed it is the ability of such compounds to potently kill cycling
cells that underlies their utility in cancer therapy (Richardson et al., 2006).
Interestingly, however, despite the sensitivity of mammalian cells to such inhibitors, the
yeast S. cerevisiae appears relatively resistant to the effects of MG132 or bortezomib
(Fleming et al., 2002; Lee and Goldberg, 1998). Part of the resistance of yeast to MG132 is
clearly due to poor uptake of these compounds into the cell (Lee and Goldberg, 1998), but
even in the presence of mutations that increase the intracellular concentration of the drug
(e.g. ise1 or Δpdr5) (Fleming et al., 2002; Lee and Goldberg, 1998) the physiological
response of yeast to these compounds is more subtle than expected. Lee and Goldberg
(1998), for example, found that ise1 yeast continue to grow when exposed to 10 µM
MG132, even under conditions in which the chymotryptic activity of the proteasome could
be inhibited by up to 95%. Similar results were reported by Fleming et al. (2002) in their
study of the effects of bortezomib on pdr5-null yeast. The modest effects of MG132 and
bortezomib on yeast proliferation contrasts strongly with the effects of these inhibitors on
mammalian cells and with the effects of a temperature-sensitive mutation in the ubiquitin
(Ub)-activating enzyme Uba1 (Ghaboosi and Deshaies, 2007) which, at the restrictive
temperature, causes a rapid arrest of yeast growth. Although the basis for these contrasting
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behaviours is not known, the lack-lustre response of yeast to compounds such as MG132
raises concern that chemical inhibition of the proteasome in S. cerevisiae is incomplete,
thereby limiting the utility of current proteasome inhibitors for studies in this species.
We reasoned that part of the resistance of yeast to chemical inhibitors of the chymotryptic
activity of the proteasome stems from the fact that, in S. cerevisiae, the tryptic- and caspase-
like sites can compensate to maintain proteasome function in the presence of inhibitors. We
therefore generated a strain of yeast in which PDR5 is deleted, and the Pup1 and Pre3
subunits of the proteasome are inactivated by mutation. We show here that this strain is
exquisitely sensitive to both reversible and irreversible chemical inhibitors of the
chymotryptic site of the proteasome. These findings highlight the importance of the tryptic-
and caspase-like activities to the physiological role of the proteasome, and provide a system




Strains used in this study are listed in Table 1. Mark Hochstrasser provided the strains of
MHY1177 and MHY1178 (Arendt and Hochstrasser, 1999). Within these strains, and the
control strain BY4742, PDR5 was replaced by the KanMX6 gene (Knop et al., 1999). The
resulting strains are GAC201 (PUP1PRE3pdr5) and GAC202 (pup1pre3pdr5 ). For α-factor
arrest experiments, GAC201 and GAC202 were converted to the a mating type by
expressing the HO endonuclease from a URA3 selectable vector [Ycp50-HO
(Krishnamoorthy et al., 2006), a gift from Shelly Berger] followed by counter-selection with
5-FOA (US Biological) to create the strains GAC201a and GAC202a. Mating type was
verified by failure to prevent the growth of bar1 yeast [RC634 (Chan and Otte, 1982), a gift
from Brehon Laurent] and by growth sensitivity to α-factor (Zymo Research).
Growth assays
Yeast cultures were grown YPAD (1% yeast extract, 2% bacto-peptone, 2% glucose, and 24
mg/l adenine hemisulfate at 30 °C to A600 = 0.2 and treated with either 50 µM MG132
(American Peptide) or an equivalent volume of DMSO (Sigma). At the indicated time
points, samples were collected and the absorbance measured at 600 nm.
For plating assays with YU101, carfilzomib and bortezomib, GAC201 and GAC202 were
grown overnight in YPD (1% yeast extract, 2% bactopeptone, 2% glucose) and diluted to
A600 = 0.3 in YP (1% yeast extract, 2% bacto-peptone). Serial five-fold dilutions were
prepared in YP and spotted onto YPD plates supplemented with various proteasome
inhibitor drugs at 10 µM (or 20 µM for carfilzomib). The plates were incubated at 30 °C for
2 days. YU101 and carfilzomib were gifts from Proteolix Inc. Bortezomib was a gift from
Millenium Pharmaceuticals.
Cell cycle analyses
GAC201a and GAC202a were arrested in G1 using 30 µM α-factor for 2 h at 25 °C. The
samples were then treated with an additional 15 mM α-factor with 50 µM MG132 (or
DMSO) for another 1 h at 25 °C. One-tenth of the culture was collected for the ‘time zero’
(t0) sample; the remaining cells were released from arrest by washing twice with YPAD
before growing in YPAD with 50 µM MG132 (or DMSO) at 30 °C. One-tenth of the culture
was collected at each of the indicated time points.
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For G2–M arrest, GAC201 and GAC202 cultures growing in YPAD were treated with 150
µg nocodazole (Sigma) for 90 min at 30 °C. The samples were then treated with an
additional 75 µg nocodazole with 50 µM MG132 (or DMSO) for 60 min. One-tenth of the
sample was collected for the ‘time zero’ (t0) point. The remaining culture was released from
arrest by washing twice with YPAD before incubating in YPAD with 50 µM MG132 (or
DMSO) at 30 °C. One-tenth of the culture was collected at each time point.
For flow cytometry, yeast cells were recovered by centrifugation, resuspended in 70%
ethanol and stored at 4 °C overnight. These cells were then washed with water, treated for
12 h at 37 °C with DNase-free RNase (Roche), sonicated, treated for 2 h at 42 °C with
proteinase K (Roche) and stored in 50 mM Tris–HCl, pH 7.5. One million cells were diluted
in 1 ml SYBR gold solution (Invitrogen) and cell cycle profiles analysed by flow cytometry,
using an LSR II cell analyser (BD Biosciences).
Anti-ubiquitin Western blot
Cultures of GAC201 and GAC202, growing in YPAD, were treated with 50 µM MG132 for
the indicated times. Proteins were extracted in EZ buffer (60 mM Tris–HCl, pH 6.8, 10%
glycerol, 2% SDS, 2% 2-mercaptoethanol), resolved on an 8% SDS–polyacrylamide gel,
and Western blotting used to detect total ubiquitin levels (anti-ubiquitin antibody MAB1510;
Millipore). Protein loading was verified by Ponceau S staining.
RNA analysis
INO1 was induced by washing yeast grown in YPAD with water and transferring to
complete synthetic medium (CSM) lacking inositol (Foremedium). ARG1 was induced by
transferring yeast to CSM lacking histidine. Induction and treatment with 50 µM MG132 (or
equivalent volume of DMSO) lasted 90 min. RNA was extracted using a hot phenol
extraction method (Muratani et al., 2005). RNA was treated with DNaseI (Invitrogen) prior
to using 1 µg RNA in a SuperScript II reverse transcriptase reaction (Invitrogen). Transcripts
were quantified using quantitative PCR (qPCR) normalized to ACT1 expression.
Results and discussion
Two previous studies (Fleming et al., 2002; Lee and Goldberg, 1998) have reported that, in
the presence of mutations that increase intracellular drug concentration, growth of common
laboratory strains of S. cerevisiae is fairly resistant to drugs that inhibit the chymotryptic
activity of the proteasome. Lee and Goldberg (1998) noted, for example, that ise1 yeast,
which are permeable to a variety of drugs (Birse et al., 1998), continue to proliferate for up
to 5 h after exposure to 10 µM MG132, despite this treatment resulting in ~95% inhibition of
the chymotryptic function of the proteasome. This result is surprising, given the central role
of proteasomal proteolysis in cell cycle progression (King et al., 1996; Zachariae and
Nasmyth, 1999) and suggests that residual activity of the proteasome is sufficient to allow
yeast to proliferate in the presence of drug.
To explore this phenomenon, we deleted the gene encoding the drug efflux pump Pdr5 from
the yeast strain BY4742 and repeated the growth analysis in the presence of MG132.
Consistent with previous reports (Fleming et al., 2002), we found that pdr5-null yeast
continue to grow for up to 16 h after exposure to 50 µM MG132 (Figure 1A), albeit at a
slightly reduced rate. Although there are numerous explanations for why yeast growth is
resistant to MG132, we reasoned that part of the explanation may stem from the fact that
MG132 preferentially inhibits the chymotryptic site of the proteasome and that, under these
conditions, the tryptic (Pup1)- and caspase (Pre3)-like sites may function to support yeast
cell viability. To test this notion, we next examined the behaviour of pdr5-null yeast in
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which the catalytic threonines of each active site within Pup1 and Pre3 are mutated to
alanine (Arendt and Hochstrasser, 1999). In the absence of MG132 (Figure 1B), the
pup1pre3pdr5 yeast grew somewhat more slowly than the congenic PUP1PRE3pdr5 control
strain, congruent with results from Arendt and Hochstrasser (1999), showing that the Pup1
and Pre3 sites within the proteasome contribute slightly to yeast cell viability. In the
presence of MG132, however, the behaviours of the two yeast strains were dramatically
different. Whereas growth of the ‘wild-type’ PUP1PRE3pdr5 strain was unaffected by
treatment with 50 µM MG132 (or 100 µM MG132; see Supporting information, Figure S1),
the pup1pre3pdr5 strain responded strongly to the drug, and essentially ceased to proliferate
under these conditions (Figure 1B). Similar results were obtained whether we monitored cell
growth by optical density (Figure 1) or by cell counting (data not shown). Response of the
pup1pre3pdr5 yeast to MG132 was sensitive to the concentration of MG132 (see Supporting
information, Figure S1) and could be reversed by transfer of cells into fresh media,
consistent with the reversible nature of MG132 inhibition of proteasome function (Groll et
al., 2009). From these data, we conclude that pup1pre3pdr5 yeast undergo a rapid and
reversible arrest of growth upon exposure to MG132. We further conclude that one or both
of the compensatory activities of the tryptic- and caspase-like sites of the proteasome help
mask the effects of MG132 (and other inhibitors of the proteasome chymotryptic site) on the
proliferative capacity of yeast. Similar effects were observed in pup1pre3PDR5 yeast treated
with 0.003% SDS (Liu et al., 2007) to promote MG132 uptake (data not shown).
Because of the pivotal role of the Ub–proteasome system in regulating cell cycle progression
(King et al., 1996; Zachariae and Nasmyth, 1999), we next asked whether pup1pre3pdr5
yeast displayed cell cycle arrest in response to MG132. Analysis of asynchronous cultures of
these cells by flow cytometry (see Supporting information, Figure S2) revealed that
pup1pre3pdr5 yeast typically had a lower percentage of cells in S-phase than their
PUP1PRE3pdr5 counterparts, but that the overall ratio of cells with 1n versus 2n DNA
content was not significantly affected by treatment with MG132. This result suggested that
MG132 restricts yeast growth at multiple points in the cell duplication cycle, consistent with
the rapid effect of the drug on yeast proliferation (Figure 1B). To ask specifically whether
two major cell cycle transitions are affected by MG132 — exit from G2–M and G1 — we
repeated the flow cytometry analyses in pup1pre3pdr5 (and control) cells that had been
arrested at either G2–M (Figure 2A) or G1 (Figure 2B), using nocodazole or α-factor,
respectively. Following release from nocodazole arrest, PUP1PRE3pdr5 yeast rapidly re-
entered the cell cycle (as judged by the appearance of cells with 1n DNA content) and the
rate at which this occurred was not significantly affected by treatment with MG132. The
pup1pre3pdr5 strain had a slower rate of re-entry into the cell cycle in the presence of
DMSO, and this rate was affected slightly by treatment with MG132; in DMSO-treated
cells, 70% of cells remained in G2–M following release of nocodazole block, whereas this
number increased to 80% upon MG132 treatment. We conclude that MG132 treatment of
pup1pre3pdr5 yeast results in a subtle reduction in the ability of these cells to transition out
of G2–M.
A strikingly different result was observed when we probed the ability of pup1pre3pdr5 yeast
to exit from G1. Following α-factor arrest, PUP1PRE3 pdr5 yeast rapidly re-entered the cell
cycle (as judged by appearance of cells with 2n DNA content), and the rate at which this
occurred was not significantly affected by treatment with MG132. The pup1pre3pdr5 strain,
in contrast, re-entered the cell cycle in the presence of the DMSO control, but in the
presence of MG132 virtually none of the cells exited G1. At the 110 min time point, for
example, the distribution of cells with 1n and 2n DNA content under these conditions was
identical to that observed in α-factor-arrested cells at t0 (Figure 2B). We conclude that
treatment of pup1pre3pdr5 yeast with MG132 blocks the ability of these cells to transition
from G1 to subsequent phases of the cell cycle.
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One of the practical uses of proteasome inhibitors such as MG132 is to promote
accumulation of Ub–protein conjugates to allow their subsequent detection by either
directed or naive methods, such as proteomic screening analyses (Mayor et al., 2007). If
indeed the Pup1 and Pre3 subunits can compensate for chemical inactivation of the
chymotryptic site, we would expect that the full spectrum of Ub–protein conjugates would
not accumulate in yeast treated with MG132 unless the proteolytic activity of these subunits
was inactivated. To address this point, we examined the levels of high molecular weight Ub-
conjugates in pup1pre3pdr5 (and control) cells treated with MG132 (Figure 3). Compared to
PUP1PRE3pdr5 cells, the triple mutant yeast again responded much more robustly to
MG132 treatment; high molecular weight Ub conjugates accumulated faster (an increase is
apparent at the 15 min time point; cf. lanes 1 and 2 with lanes 6 and 7) and to a significantly
higher level (cf. lanes 5 and 10). This result provides molecular support for the notion that
one or both of the Pup1 and Pre3 subunits of the proteasome functionally compensate for
Pre2-mediated destruction of ubiquitylated proteins in the presence of MG132. Importantly,
these results also demonstrate that a combined chemical and genetic strategy to inhibit
proteasomal proteolysis can be used significantly enhance detection of ubiquitylated
proteins in yeast.
In addition to MG132, we were interested in asking whether pup1pre3pdr5 yeast also had
enhanced sensitivity to other inhibitors of the chymotryptic site of the proteasome. For this
analysis, we chose the reversible inhibitor bortezomib, as well as two irreversible inhibitors,
YU101, a derivative of epoxomicin (Bo Kim et al., 2005), and carfilzomib, another
derivative of epoxomicin that has been taken to clinical trials (Kuhn et al., 2007). We
assayed the ability of these compounds to inhibit yeast growth on solid media, as shown in
Figure 4. Consistent with our earlier findings, treatment of PUP1PRE3pdr5 yeast with these
compounds had little if any effect on yeast growth under these conditions. Growth of the
pup1pre3pdr5 yeast, in contrast, was strongly inhibited by all three compounds, with the
greatest attenuation of growth observed in the presence of 20 µM carfilzomib (cf. growth of
pup1pre3pdr5 yeast on YPD vs medium containing the proteasome inhibitors). These data
demonstrate that genetic inactivation of the catalytic activity of Pup1 and Pre3 renders yeast
generally susceptible to chemical inhibition of the chymotryptic site of the proteasome.
Finally, we examined the effects of MG132 on gene induction in the pup1pre3pdr5 strain. A
growing body of evidence supports a role for the Ub–proteasome system in the regulation of
a diverse set of genes (Lipford and Deshaies, 2003; Muratani and Tansey, 2003), although
whether proteasome inhibition via MG132 disrupts gene activation in S. cerevisiae is
controversial (Collins et al., 2009; Lipford et al., 2005; Nalley et al., 2006). Given the
striking effects of MG132 we observe in pup1pre3pdr5 cells (Figures 1–4), we decided to
re-examine this issue under circumstances where we could be confident that we had
comprehensively inhibited proteasome function. We were not able to examine GAL
induction, because this strain background is unable to utilize galactose as a carbon source
(not shown). For this analysis, therefore, we selected two strongly induced target genes that
are regulated by different stimuli: (a) ARG1, which is induced by amino acid starvation via
the Gcn4 activator (Crabeel et al., 1995); and (b) INO1, which is induced by inositol
starvation via the Ino2 and Ino4 transcription factors (Ambroziak and Henry, 1994). We
added 50 µM MG132 60 min prior to induction and examined transcript levels from each
gene in the congenic PUP1PRE3pdr5 and pup1pre3pdr5 strains an additional 60 min after
induction. The results of this analysis are shown in Figure 5. For ARG1, we consistently
observed a small but significant effect of MG132 on induction in the PUP1PRE3pdr5 cells
(Figure 5A) and, as expected, the magnitude of the effect of MG132 was increased in the
pup1pre3pdr5 background. For INO1, the effects of the Pup1/Pre3 mutations on response to
MG132 were even more dramatic; in the PUP1PRE3pdr5 setting, INO1 induction was
completely insensitive to MG132 (Figure 5B), whereas in the pup1pre3pdr5 cells, INO1
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induction was substantially reduced by MG132 treatment. Thus, as with growth, cell cycle
perturbation and accumulation of Ub conjugates, the trypticand/or caspase-like activities of
the proteasome appear to mask the full effects of MG132 on gene induction in vivo. We
conclude that, when the proteasome is effectively inhibited using this combined chemical
and genetic approach, transcriptional activation can be significantly compromised.
Concluding remarks
We report here a strategy for comprehensively inhibiting proteasome function in S.
cerevisiae by combining genetic ablation of the tryptic and caspase-like protease sites with
transient chemical inhibition of the chymotryptic site within the proteasome. Using this
strategy, we observed robust effects of MG132 and other inhibitors on yeast cell growth, cell
cycle progression, accumulation of Ub-conjugates and transcriptional activation. These
results highlight the contribution of the tryptic- and caspase-like protease sites to proteasome
function in yeast, and provide a setting in which compounds such as MG132 can become
potent transient inhibitors of proteasome function. The dramatically enhanced sensitivity of
the pup1pre3pdr5 strain to MG132, bortezomib, YU101 and carfilzomib should prove useful
for detection of Ub–protein conjugates, and for probing the role of proteasomal proteolysis
in processes such as transcription, DNA repair, protein quality control and organelle
dynamics.
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Effect of MG132 on S. cerevisiae growth. (A) BY4742 Δpdr5::KanMX6 were treated with
either DMSO or 50 µM MG132 and growth measured as increase in the absorbance (A600
nm) of the culture. (B) As in (A) except that strains GAC201 (PUP1PRE3pdr5) and
GAC202 (pup1pre3pdr5) were used. In all cases, data are from three independent
experiments with errors representing standard error of the mean (SEM)
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Effect of MG132 on cell cycle progression in pup1pre3pdr5 yeast. (A) PUP1PRE3pdr5
(GAC201) and pup1pre3pdr5 (GAC202) yeast were arrested at G2–M by treatment with
nocodazole. They were then treated with DMSO or 50 µM MG132 and released from arrest.
At the indicated times, samples were collected, and flow cytometry performed to determine
the profiles of DNA content. (B) PUP1PRE3pdr5 (GAC201a) and pup1pre3pdr5
(GAC202a) yeast were arrested at G1 by treatment with α-factor. They were then treated
with DMSO or 50 µM MG132 and released from arrest. At the indicated times, samples
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were collected and flow cytometry performed to determine the profiles of DNA content.
Representative examples of three biologically independent replicates are shown
Collins et al. Page 12














Analysis of high molecular weight ubiquitin conjugates in pup1pre3pdr5 yeast upon
treatment with MG132. (A) Anti-ubiquitin Western blot of whole cell extracts from
PUP1PRE3pdr5 (GAC201) and pup1pre3pdr5 (GAC202) yeast treated with 50 µM MG132
for the indicated times. (B) Ponceau S staining of the membrane to demonstrate equivalent
loading of whole cell extracts into the gel. A representative of two independent experiments
is shown
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Sensitivity of pup1pre3pdr5 yeast to multiple proteasome inhibitors. Serial five-fold
dilutions of PUP1PRE3PDR5 (MHY1177), pup1pre3PDR5 (MHY1178), PUP1PRE3pdr5
(GAC201), and pup1pre3pdr5 (GAC202) were spotted onto YPD, YPD + MG132 (10 µM),
YPD + bortezomib (10 µM), YPD + Y101 (10 µM) and YPD + carfilzomib (20 µM) plates
prior to growth for two days at 30 °C. A representative of two independent experiments is
shown
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Effect of MG132 on transcription induction in pup1pre3pdr5 yeast. (A) PUP1PRE3pdr5
(GAC201) and pup1pre3pdr5 (GAC202) cells were treated with 50 µM MG132 (or DMSO)
prior to induction by histidine starvation. RNA was harvested and RT–QPCR used to
determine ARG1 transcript levels, relative to those of ACT1; n = 4, SEM. (B) As in (A)
except that induction was by inositol starvation and INO1 RNA levels were monitored; n =
3, SEM
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Table 1
Strains used in this study
Strain Genotype Source
BY4742 Δpdr5::KanMX6 Matα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 pdr5Δ::KanMX6 This study








GAC201 Matα his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 pdr5Δ::KanMX6 pre3-Δ2::HIS3
pup1 Δ::leu2-HIS3 [pRS317-PUP1] [YCplac22-PRE3] gal−
This study
GAC202 Matα his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 pdr5Δ::KanMX6 pre3-Δ2::HIS3
pup1Δ::leu2-HIS3 [pRS317-pup1-T30A] [YCplac22-pre3-T20A] gal−
This study
GAC201a Mata his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 pdr5Δ::KanMX6 pre3-Δ2::HIS3
pup1Δ::leu2-HIS3 [pRS317-PUP1] [YCplac22-PRE3] gal−
This study
GAC202a Mata his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 pdr5Δ::KanMX6 pre3-Δ2::HIS3
pup1Δ::leu2-HIS3 [pRS317-pup1-T30A] [YCplac22-pre3-T20A] gal−
This study
RC634 Mata rme1 ade2-1 ura1 his6 met1 can1 cyh2 sst1-3 Chan and Otte, 1982
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